Pfizer and BioMarin have pulled their hemophilia gene therapies, citing low demand. To prepare for his presentation at the ...
Food and Drug Administration is considering approving testosterone replacement therapy ‌to treat low sex drive in men whose ...
High co-payments for potentially curative cell and gene therapies create avoidable access barriers; value-based insurance ...
Peripheral nerve injuries, often caused by traumatic events such as car accidents, falls or battlefield injuries, can leave patients with long-term weakness, numbness or loss of function. Despite ...
2d
U.S. FDA Grants RMAT Designation to GS-100, Grace Science’s Gene Therapy to Treat NGLY1 Deficiency
Grace Science, LLC, a biotechnology company founded to develop novel therapies based on the function of NGLY1, announced ...
Scientists have developed a new gene therapy that quiets pain at its source in the brain—without the addictive risks of opioids. Using AI to map how pain is processed, they created a targeted “off ...
Key takeaways• Researchers at The Ohio State University College of Medicine and College of Engineering developed a novel gene ...
The FDA may allow broader access to testosterone therapy for men with low libido without known medical cause. Manufacturers ...
RMAT designation enables intensified FDA engagement and potential accelerated pathways, implying preliminary clinical evidence for RTx-015 despite absent peer-reviewed efficacy details, endpoints, and ...
Company entered into an asset purchase agreement with Johnson & Johnson (J&J) to acquire all interests in botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP ...
FDA is encouraging supplemental NDAs for TRT to treat low libido in idiopathic hypogonadism, reflecting preliminary ...
Clinically meaningful improvements in xerostomia symptoms measured by PRO Xerostomia Questionnaire (XQ) maintained out to 3 years post treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results